keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28814312/rationale-and-design-of-the-brigham-cohort-for-psoriasis-and-psoriatic-arthritis-registry-coppar
#1
Maria Schneeweiss, Joseph F Merola, Elizabeth W Karlson, Daniel H Solomon
BACKGROUND: Psoriasis (PsO) and psoriatic arthritis (PsA) are related conditions with poorly defined transition among them, risk factors for progression, complex treatment algorithms, and biomarkers for treatment response and long-term outcomes. We describe the development of a PsO/PsA registry at an academic medical center. METHODS: We developed a single-center PsO/PsA longitudinal disease registry including biorepository that captures relevant disease markers and treatment choices in a circumscribed population with a defined catchment area...
August 16, 2017: BMC Dermatology
https://www.readbyqxmd.com/read/28809995/efficacy-and-safety-of-apremilast-in-patients-with-moderate-plaque-psoriasis-with-lower-bsa-week-16-results-from-the-unveil-study
#2
Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
<p>INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clearance. UNVEIL (NCT02425826) assessed efficacy and safety of apremilast in patients with chronic moderate plaque psoriasis.</p> <p>METHODS: Patients with psoriasis body surface area (BSA) 5% to 10% and static Physician's Global Assessment (sPGA) score of 3 (moderate) without prior exposure to systemics were randomized (2:1) to apremilast 30 mg twice daily or placebo for 16 weeks...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809994/the-static-physician-s-global-assessment-of-genitalia-a-clinical-outcome-measure-for-the-severity-of-genital-psoriasis
#3
Joseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, Alan Menter, April N Naegeli, Robert Bissonnette, Lyn Guenther, John Sullivan, Kim Meeuwis, Kyoungah See, Kristina Callis Duffin
<p>Introduction: Genital psoriasis is a common but frequently overlooked manifestation of psoriasis with a considerable impact on patients' quality of life. Currently no validated clinical trial outcome measures exist to assess genital psoriasis severity that meet regulatory agency requirements.</p> <p>Methods: This study describes the development of the static Physician's Global Assessment of Genitalia (sPGA-G) scale, a clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809993/adalimumab-in-chronic-plaque-psoriasis-a-clinical-guide
#4
Jashin J Wu, W C Valdecantos
<p>Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treatment in psoriasis is to improve the signs and symptoms of disease, whilst minimizing the burden of disease on patient health-related quality of life. Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28797188/validation-of-psychometric-properties-and-development-of-response-criteria-for-the-psoriasis-symptoms-and-signs-diary-pssd-results-from-a-phase-iii-clinical-trial
#5
April Armstrong, Luis Puig, Richard Langley, Tsen Fang Tsai, Michael Song, Yasmine Wasfi, Jingzhi Jiang, Shu Li, Chenglong Han
PURPOSE: The Psoriasis Symptoms and Signs Diary (PSSD) is a patient-reported instrument that assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding). MATERIALS AND METHODS: PSSD symptoms and signs summary scores (0-100) were derived based on individual item scores (0-10 [absent-worst imaginable]). Using Psoriasis Area and Severity Index [PASI], Investigator's Global Assessment [IGA] and Dermatology Life Quality Index [DLQI]) data from the NAVIGATE trial of patients with moderate-to-severe psoriasis, analyses were conducted to further validate the PSSD (7-day recall version) and establish criteria for clinically meaningful improvements (CMIs)...
August 11, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28796913/patients-with-psoriasis-have-different-preferences-for-topical-therapy-highlighting-the-importance-of-individualized-treatment-approaches-randomized-phase-iiib-pso-insightful-study
#6
C-H Hong, K A Papp, K W Lophaven, P Skallerup, S Philipp
BACKGROUND: Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life, and increased costs. Treatment-related factors leading to poor adherence include lack of efficacy, excessive time applying medication, and poor cosmetic characteristics (e.g. slow absorption, greasiness). OBJECTIVE: To assess the topical treatment attributes that influence patient preference for fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0...
August 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28795763/determinants-of-psychosocial-health-in-psoriatic-patients-a-multi-national-study
#7
Karolina Lesner, Adam Reich, Jacek C Szepietowski, Florence J Dalgard, Uwe Gieler, Lucía Tomas-Aragones, Lars Lien, Françoise Poot, Gregor B Jemec, Laurent Misery, Csanád Szabó, Dennis Linder, Francesca Sampogna, Andrea W M Evers, Jon Anders Halvorsen, Flora Balieva, Andrey Lvov, Servando E Marron, Ilknur K Altunay, Andrew Y Finlay, Sam S Salek, Jörg Kupfer
There are limited data on the differences in the impact of psoriasis between various countries with respect to quality of life (QoL). The aim of this study was to explore the psychosocial health of patients with psoriasis in different European countries. A total of 682 patients were recruited in 13 European countries. All patients completed a questionnaire regarding socio-demographic information, negative life events, suicidal ideation and satisfaction with their dermatologist. Depression and anxiety were assessed with the Hospital Anxiety and Depression Scale (HADS), and QoL with the Dermatology Life Quality Index (DLQI) and EuroQoL (EQ-5D)...
August 10, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28777015/is-weekly-dose-of-adalimumab-a-simple-approach-for-resistant-psoriasis
#8
Sara Mazzilli, Arianna Zangrilli, Mauro Bavetta, Luca Bianchi
Backgroud: In real life, dose escalation can be a good approach for increasing efficacy in a subgroup of patients with an insufficient response to biologic therapy, reducing the signs and symptoms of psoriasis and improving the quality of life (QOL). OBJECTIVE: To determine the effectiveness of escalating adalimumab dosage from 40 mg eow to 40 mg weekly in a patient affected by psoriasis (PsO) and psoriatic arthritis (PsA) with < PASI 50 response following 364 weeks treatment...
August 4, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28771657/time-pasi-and-dlqi-of-psoriasis-patients-who-drop-out-of-clinical-trials-on-etanercept-due-to-lack-of-efficacy-a-pooled-analysis-from-ten-clinical-trials
#9
A Nast, M Dilleen, W Liyanage, L Aikman, P Szczypa, C Dressler
BACKGROUND: Patient-reported outcomes in psoriasis studies are assessed at specific study time points. If a treatment has not become effective by a certain time point, it may increase the likelihood of patients being dissatisfied and leaving a clinical study. OBJECTIVES: Generate evidence concerning the number of patients dropping out of etanercept trials over time including PASI and DLQI data. METHODS: Data from psoriasis patients in ten trials with etanercept were pooled...
August 3, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28769136/nail-involvement-in-psoriatic-arthritis
#10
REVIEW
Piotr Sobolewski, Irena Walecka, Klaudia Dopytalska
Nail psoriasis is considered a significant psychological and social problem causing functional impairment in affected patients. Nail changes hamper their daily and occupational activities and contribute to a worse quality of life. Almost 50% of patients with psoriasis vulgaris and up to 80% of patients with psoriatic arthritis are afflicted with nail lesions. The important correlation between psoriatic arthritis and nail changes is well established - the presence of the latter is a strong predictor of the development of arthritis...
2017: Reumatologia
https://www.readbyqxmd.com/read/28761839/a-real-world-study-to-assess-the-effectiveness-of-itolizumab-in-patients-with-chronic-plaque-psoriasis
#11
Anchala Parthasaradhi, Vinay Singh, S G Parasramani, Nishi Yadav, D S Krupashankar, Manish Soni, Rakesh Bansal
BACKGROUND: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. AIMS: The current study assessed the effectiveness of itolizumab in real-world settings. MATERIALS AND METHODS: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore...
July 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28754116/how-is-disease-severity-associated-with-quality-of-life-in-psoriasis-patients-evidence-from-a-longitudinal-population-based-study-in-sweden
#12
Kirk Geale, Martin Henriksson, Marcus Schmitt-Egenolf
BACKGROUND: Assessing the impact of disease severity on generic quality of life (QOL) is a critical step in outcomes research and in the development of decision-analytic models structured around health states defined by clinical measures. While data from routine clinical practice found in healthcare registers are increasingly used for research, more attention should be paid to understanding the relationship between clinical measures of disease severity and QOL. The purpose of this work was therefore to investigate this relationship in psoriasis using a population-based dataset...
July 28, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28748378/validation-of-an-egyptian-arabic-version-of-skindex-16-and-quality-of-life-measurement-in-egyptian-patients-with-skin-disease
#13
Nagwa Essa, Sara Awad, Mariam Nashaat
PURPOSE: To translate and cross-culturally adapt the Skindex-16, a brief skin-disease-specific QoL questionnaire, into Arabic for Egyptians and to evaluate its measurement properties in Egyptian patients with skin disease. METHOD: Translation and cultural adaption were performed following guidelines for cross-cultural adaption of health-related quality of life measures. Subsequently, Skindex-16 was administered to 500 consecutive dermatological patients and 500 healthy persons for verification of its reliability and validity...
July 26, 2017: International Journal of Behavioral Medicine
https://www.readbyqxmd.com/read/28737440/secukinumab-improves-scalp-pain-itching-scaling-and-quality-of-life-in-patients-with-moderate-to-severe-scalp-psoriasis
#14
Steven R Feldman, Lawrence Green, Alexa B Kimball, Kimberly Siu, Yang Zhao, Vivian Herrera, Judit Nyirady, Andrew F Alexis
INTRODUCTION: Scalp psoriasis adversely affects patients' lives and is often resistant to treatment however it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis. METHODS: A randomized, double-blind, placebo-controlled, multicenter study was conducted in 102 adult patients with moderate-to-severe scalp psoriasis. Patients were randomized 1:1 to secukinumab 300mg or placebo...
July 24, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28735828/investigation-of-dietary-supplements-prevalence-as-complementary-therapy-comparison-between-hospitalized-psoriasis-patients-and-non-psoriasis-patients-correlation-with-disease-severity-and-quality-of-life
#15
Hadis Yousefzadeh, Mahmoud Mahmoudi, Mahnaz Banihashemi, Maryam Rastin, Farahzad Jabbari Azad
OBJECTIVES: Psoriasis patients are often displeased with traditional medical treatments and they may self-prescribe dietary supplements as an alternative or complementary treatments. We aimed to investigate the prevalence of self-medication of dietary supplements among psoriasis and non-psoriasis cases and its impact on disease severity and quality of life. DESIGN AND SETTING: This case-control study evaluated 252 records of psoriasis patients and 245 non-psoriasis cases...
August 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/28735350/inflammatory-joint-disorders-and-neutrophilic-dermatoses-a-comprehensive-review
#16
REVIEW
Massimo Cugno, Roberta Gualtierotti, Pier Luigi Meroni, Angelo Valerio Marzano
Rheumatoid arthritis and spondyloarthritis are inflammatory joint disorders with an autoimmune pathogenesis and systemic involvement. The skin is one of the most frequently affected extraarticular sites with a number of manifestations or distinct diseases, including common conditions, such as rheumatoid nodules and psoriasis, and rare diseases like neutrophilic dermatoses. The latter are clinically characterised by polymorphic lesions, including pustules, bullae, abscesses, papules, nodules, plaques and ulcers, and histologically by neutrophil-rich inflammatory infiltrates...
July 22, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28722209/reporting-of-outcomes-in-randomised-controlled-trials-on-nail-psoriasis-a-systematic-review
#17
REVIEW
C I M Busard, J Y C Nolte, M C Pasch, Ph I Spuls
Harmonization of outcome measures is needed to increase the value of clinical trials on nail psoriasis. To provide the first step in core outcome set (COS) development, a systematic review was conducted to identify outcome domains and instruments reported in (ongoing) randomised controlled trials (RCTs) on nail psoriasis. Identified outcome domains included clinical signs, quality of life, symptoms and delivery of care. A NAPSI was most commonly used to assess clinical signs (73.8% of studies). Other outcome instruments used included the NAS, composite fingernail score, a physician global assessment, individual nail features or a combination of these...
July 19, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28714180/tofacitinib-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-in-japanese-patients-subgroup-analyses-from-a-randomized-placebo-controlled-phase-3-trial
#18
Masatoshi Abe, Chikako Nishigori, Hideshi Torii, Hironobu Ihn, Kei Ito, Makoto Nagaoka, Naoki Isogawa, Isao Kawaguchi, Yukiko Tomochika, Mihoko Kobayashi, Anna M Tallman, Kim A Papp
Tofacitinib is an oral Janus kinase inhibitor. These post-hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52-week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo-treated patients advanced to tofacitinib at week 16. Primary efficacy end-points were the proportions of patients with 75% or more reduction from baseline Psoriasis Area and Severity Index (PASI-75) and Physician's Global Assessment (PGA) of "clear" or "almost clear" (PGA response) at week 16...
July 17, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28711022/pre-clinical-efficacy-assessment-of-malva-sylvestris-on-chronic-skin-inflammation
#19
Arthur S Prudente, Graziela Sponchiado, Daniel A G B Mendes, Bruna S Soley, Daniela A Cabrini, Michel F Otuki
In the search for improved quality of life, the treatment of skin diseases like psoriasis (hyperproliferative disease) is valid, since it causes huge social discomfort to the patient. In this context, earlier studies showed that Malva sylvestris L. has anti-inflammatory activity demonstrated by acute animal models of skin inflammation, becoming a promising target for further studies. The present investigation aimed to verify the effect of hydroalcoholic extract of M. sylvestris (HEMS) on the chronic inflammatory and hyperproliferative response caused by multiple applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) on mouse ears...
September 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28694859/interplay-between-prolactin-and-pathogenesis-of-psoriasis-vulgaris
#20
Delia Botezatu, Mihaela Tovaru, Simona-Roxana Georgescu, Oana-Diana Leahu, Calin Giurcaneanu, Antoanela Curici
INTRODUCTION: The polypeptide hormone prolactin (PRL) represents the pituitary modulator of lactation and reproduction. Currently, we discuss the wide range of PRL actions "beyond the mammary horizon". Multiple studies had showed the role of PRL as a cytokine, with comparable structural motifs, similar receptor structures and signal transduction pathways. Almost two decades ago it was fi rst hypothesized that PRL acts as a neuroendocrine modulator of both skin epithelial growth and the skin immune system...
September 2016: Mædica
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"